Quarterly ResultMay 7, 2026, 08:44 AM
Theravance Biopharma Q1 Net Loss $4.9M; Restructuring & Strategic Review Progress
AI Summary
Theravance Biopharma reported improved financial results for Q1 2026, with total revenue reaching $17.7 million, a 15% increase year-over-year, and a reduced net loss of $4.9 million. The company's organizational restructuring is on track, leading to a ~20% reduction in Q1 operating expenses and an anticipated 60% overall reduction for $60-$70 million in annualized cash flow from Q3 2026. A Strategic Review Committee is actively evaluating options to maximize shareholder value, including a potential sale of the company.
Key Highlights
- Strategic Review Committee actively evaluating a range of opportunities, including a sale of the company.
- Organizational restructuring on track; Q1 operating expenses (excluding restructuring) reduced ~20% year-over-year.
- Expects 60% operating expense reduction, resulting in $60-$70M annualized cash flow from Q3 2026.
- Q1 2026 total revenue was $17.7M, an increase of 15% compared to Q1 2025.
- Q1 2026 net loss was $4.9M, an improvement from a $13.6M net loss in Q1 2025.
- YUPELRI collaboration revenue increased 15% year-over-year to $17.7M.
- TRELEGY Q1 global net sales were $873M, up 2% YoY; confident in achieving $100M 2026 milestone payment.
- Quarter-end cash balance of $395M with no debt.